© 2021 MJH Life Sciences™ and Neurology Live. All rights reserved.
Buffalo Neuroimaging Analysis Center
BNAC is a leading neuroimaging research center extending the boundaries of knowledge about neurological disease and disorders through innovative research techniques and advanced neuroimaging bioinformatics. BNAC scientists perform pre-clinical and clinical trials as well as patient-centered, investigator-initiated studies with specialization in MS, Parkinson’s Disease, stroke.
Led since 2003 by its Director Robert Zivadinov, MD, Ph.D., the Center is part of the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, State University of New York.
Latest from Buffalo Neuroimaging Analysis Center
Applying Artificial Intelligence and Neuroimaging Into Clinical Care: Michael Dwyer, PhD
September 16, 2021
Video
The director of IT and Neuroinformatics Development at the Buffalo Neuroimaging Analysis Center provided a realistic perspective of when and how AI will be incorporated into the wider medical system.
NeuroVoices: Michael Dwyer, PhD, on Clinical Impact of AI in Neuroimaging
September 15, 2021
Article
The director of IT and Neuroinformatics Development at the Buffalo Neuroimaging provided thoughts on artificial intelligence’s role in neuroimaging and treating multiple sclerosis.
Techniques, Biomarkers, and Hot Topics in Neuroimaging: Michael Dwyer, PhD
September 14, 2021
Video
The director of IT and Neuroinformatics Development at the Buffalo Neuroimaging Analysis Center provided thoughts on the trending topics within the neuroimaging space.
Artificial Intelligence’s Capabilities in Neuroimaging: Michael Dwyer, PhD
September 09, 2021
Video
The director of IT and Neuroinformatics Development at the Buffalo Neuroimaging Analysis Center discussed the potential advantages AI-built neuroimaging brings to neurology.
Atrophied Lesion Volume as a Biomarker of Disability in Progressive Multiple Sclerosis
June 29, 2021
Article
Robert Zivadinov, MD, PhD, director, Buffalo Neuroimaging Analysis Center, spoke to the findings of a post-hoc analysis of atrophied T2-lesion volume as a biomarker in patients with progressive MS.
Developing the aT2-LV Biomarker for Progressive MS
June 02, 2021
Article
Robert Zivadinov, MD, PhD, professor of neurology and director of the Buffalo Neuroimaging Analysis Center, discussed the post-hoc analysis of the ORATORIO trial he and colleagues conducted.